Technical Trend Evolution and Price Movement
The stock closed at ₹2,395.00 on 30 Sep 2026, marking a 2.53% gain from the previous close of ₹2,336.00. This uptick brings the price closer to its 52-week high of ₹2,536.85, while comfortably above the 52-week low of ₹1,794.00. The daily trading range between ₹2,290.60 and ₹2,395.00 reflects increased buying interest and price momentum.
Technically, Glenmark’s trend has upgraded from mildly bullish to bullish, signalling stronger upward momentum. The daily moving averages have turned decisively bullish, reinforcing the positive price action. This is a critical development as moving averages often act as dynamic support and resistance levels, and their bullish alignment typically attracts momentum-driven investors.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a robust bullish signal on both weekly and monthly timeframes. The weekly MACD line remains above its signal line, indicating sustained upward momentum in the near term. Similarly, the monthly MACD confirms a longer-term bullish trend, suggesting that the stock’s positive momentum is not merely a short-lived phenomenon.
However, the Relative Strength Index (RSI) on weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This implies that while momentum is positive, the stock is not yet overbought, leaving room for further upside without immediate risk of a technical correction.
Bollinger Bands and Volatility Assessment
Bollinger Bands on the weekly chart are bullish, with the price trending near the upper band, indicating strong buying pressure. On the monthly scale, the bands are mildly bullish, suggesting moderate volatility but a positive directional bias. This combination points to a controlled but optimistic price environment, where volatility is present but not excessive.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Other Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator presents a mixed picture. On the weekly timeframe, it is bullish, supporting the recent positive momentum. However, the monthly KST is mildly bearish, signalling some caution for longer-term investors. This divergence suggests that while short-term momentum is strong, longer-term trend confirmation is still evolving.
Dow Theory readings add further nuance. The weekly Dow Theory is mildly bearish, indicating some short-term market hesitancy or consolidation phases. The monthly Dow Theory shows no clear trend, reflecting uncertainty in the broader market context. Meanwhile, the On-Balance Volume (OBV) indicator is mildly bullish on the weekly chart, signalling that volume supports the recent price gains, though monthly OBV remains neutral.
Comparative Performance Against Sensex
Glenmark Pharmaceuticals has outperformed the Sensex significantly over multiple time horizons. Year-to-date, the stock has delivered a 17.64% return compared to the Sensex’s negative 14.89%. Over one year, Glenmark’s return stands at 22.27%, while the Sensex declined by 9.75%. The outperformance is even more pronounced over longer periods, with a three-year return of 180.18% versus Sensex’s 10.18%, and a five-year return of 370.35% compared to Sensex’s 22.08%. Even on a decade scale, Glenmark’s 163.84% return slightly surpasses the Sensex’s 160.64%, underscoring its strong growth trajectory within the Pharmaceuticals & Biotechnology sector.
Mojo Score and Rating Revision
MarketsMOJO has recently revised Glenmark’s Mojo Grade from Buy to Hold as of 28 Sep 2026, reflecting a more cautious stance amid evolving technical and fundamental factors. The current Mojo Score stands at 65.0, indicating moderate confidence in the stock’s near-term prospects. The mid-cap classification aligns with Glenmark’s market capitalisation and growth profile, positioning it as a key player in the Pharmaceuticals & Biotechnology industry.
Investment Implications and Outlook
The technical momentum shift to a bullish trend, supported by MACD and moving averages, suggests that Glenmark Pharmaceuticals is poised for potential further gains. The absence of overbought RSI conditions provides room for upside, while the mixed signals from KST and Dow Theory advise measured optimism. Investors should monitor volume trends and broader market conditions closely, as these will influence the sustainability of the current rally.
Glenmark Pharmaceuticals Ltd. or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary
Glenmark Pharmaceuticals Ltd. is currently exhibiting a strengthened technical profile, with key indicators signalling a bullish momentum shift. While some longer-term indicators suggest caution, the overall trend is positive, supported by solid volume and moving average alignments. The stock’s consistent outperformance relative to the Sensex over multiple timeframes further bolsters its investment appeal within the Pharmaceuticals & Biotechnology sector. Investors should weigh the recent Mojo Grade downgrade against the technical improvements to make informed decisions aligned with their risk tolerance and investment horizon.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
